Michael Barbella, Managing Editor06.03.21
Arthrolense Inc., has completed a funding round with Toronto-based private equity firm Lynx Equity Limited. Terms of the deal were not disclosed.
Founded in 2019 by orthopedic physicians Russell Nevins, M.D. of Las Vegas, and David Backstein, M.D., of Toronto, Ontario, Arthrolense develops real-time, hologram-based navigation systems for surgical procedures. Arthrolense’s initial product development activities are targeting unmet needs and opportunities in high-volume orthopedic procedures including hip and knee arthroplasty.
“The advent of high powered gaming engines in concert with advanced wearable optics have catalyzed a vast new innovation space, and Arthrolense’s patented and proprietary technology is pushing new boundaries to explore the seamless integration of real-time digital imaging with surgeon-controlled medical instrumentation,” explained Backstein.
Through the incorporation of three-dimensional spatial mapping and proprietary multi-axis marker placards, the Arthrolense technology enables physicians to visualize the effects and results of tissue cuts and preparatory procedures automatically with no pre-operative scans and no time-consuming bone array placements.
“New medical technologies often add time to surgery and end up being complicated for the user and expensive for the institution,” noted Nevins. “But the Arthrolense system is engineered to integrate seamlessly with the current surgical flow in an intuitive and beneficial manner. And, by eliminating the typical touchscreen and foot pedal setup, we empower physician users to interact using gestures and voice commands, an ideal configuration for busy surgeons and particularly those operating at ambulatory surgical centers.”
Arthrolense intends to use the funds from Lynx Equity to complete its product design history file (DHF), embark on an initial 510(k) regulatory filing with the U.S. Food and Drug Administration, and bolster the company’s expanding intellectual property portfolio in advance of global commercialization.
Based in Toronto, Arthrolense is a medical technology firm focused on the development and commercialization of hologram-based surgical navigation systems. Arthrolense holds multiple pending and issued patents and develops operating-room based solutions that leverage augmented and mixed reality technology to deliver real-time, actionable datasets to operating physicians.
Founded in 2019 by orthopedic physicians Russell Nevins, M.D. of Las Vegas, and David Backstein, M.D., of Toronto, Ontario, Arthrolense develops real-time, hologram-based navigation systems for surgical procedures. Arthrolense’s initial product development activities are targeting unmet needs and opportunities in high-volume orthopedic procedures including hip and knee arthroplasty.
“The advent of high powered gaming engines in concert with advanced wearable optics have catalyzed a vast new innovation space, and Arthrolense’s patented and proprietary technology is pushing new boundaries to explore the seamless integration of real-time digital imaging with surgeon-controlled medical instrumentation,” explained Backstein.
Through the incorporation of three-dimensional spatial mapping and proprietary multi-axis marker placards, the Arthrolense technology enables physicians to visualize the effects and results of tissue cuts and preparatory procedures automatically with no pre-operative scans and no time-consuming bone array placements.
“New medical technologies often add time to surgery and end up being complicated for the user and expensive for the institution,” noted Nevins. “But the Arthrolense system is engineered to integrate seamlessly with the current surgical flow in an intuitive and beneficial manner. And, by eliminating the typical touchscreen and foot pedal setup, we empower physician users to interact using gestures and voice commands, an ideal configuration for busy surgeons and particularly those operating at ambulatory surgical centers.”
Arthrolense intends to use the funds from Lynx Equity to complete its product design history file (DHF), embark on an initial 510(k) regulatory filing with the U.S. Food and Drug Administration, and bolster the company’s expanding intellectual property portfolio in advance of global commercialization.
Based in Toronto, Arthrolense is a medical technology firm focused on the development and commercialization of hologram-based surgical navigation systems. Arthrolense holds multiple pending and issued patents and develops operating-room based solutions that leverage augmented and mixed reality technology to deliver real-time, actionable datasets to operating physicians.